ArticleAmerican journal of preventive cardiology2026
Cardiovascular risk goal attainment in the United States rheumatologic population.
Article in American journal of preventive cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rheumatologic diseases are independently linked to premature cardiovascular (CV) events. The emerging field of cardio-rheumatology addresses the intersection of inflammation and accelerated atherosclerosis driving excess CV risk. Despite calls to action, data on risk factor optimization, antihyperlipidemic therapy, and comorbidities remain limited. Using the largest US analytic cohort to date, we examined antihyperlipidemic prescription patterns in patients with rheumatologic disease and elevated atherosclerotic cardiovascular disease (ASCVD) risk. Methods: We analyzed deidentified EPIC Cosmos records (277 million patients, 1,597 hospitals, 17 billion encounters) from 1/2020-1/2025. Adults with any of 11 rheumatologic conditions associated with elevated CV risk-including rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, ankylosing spondylitis, and systemic sclerosis-were included. We described prevalence of elevated ASCVD risk (=7.5%), prescription rates of antihyperlipidemic therapy and attainment of guideline directed LDL-C <70 mg/dL. Results: Among ≈4 million included patients, ASCVD-related comorbidities were common: diabetes (19.6%), hypertension (52.1%), dyslipidemia (51.4%). Mean LDL was 98 mg/dL; mean A1c was 7.1% in diabetics and 5.6% in nondiabetics. Only 18.1% achieved LDL <70 mg/dL during the study period. Despite 41.9% having a Cardiology and 36.4% a Rheumatology encounter, 22.7% of dyslipidemic patients were not on antihyperlipidemic therapy. Among those with ASCVD risk 7.5-20%, 28.5% were not on antihyperlipidemic therapy (17.0% with myalgias). For ASCVD risk >20%, 19.9% were not on antihyperlipidemic therapy (17.3% with myalgias). Conclusion: In this large US cohort, lipid management and CV risk goal attainment were suboptimal across rheumatologic conditions. These findings underscore the need for multidisciplinary cardio-rheumatology care and implementation strategies to improve outcomes in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.